Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist into adulthood. The standard treatment option for AD patients is topical immunotherapy, which has proven broadly effective in managing symptoms. In topical-refractory patients, symptoms are commonly managed by systemic immunomodulators, which pose potentially serious side effects when administered over the long term. The launches of Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent have expanded treatment options for AD patients across the severity spectrum. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug treatment trends in AD.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Sanofi, Regeneron, Eli Lilly, Incyte, AbbVie
Key drugs: Dupixent, Eucrisa, Olumiant, Rinvoq, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids and calcineurin inhibitors